Graphite Bio, Inc. (GRPH) News
Filter GRPH News Items
GRPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest GRPH News From Around the Web
Below are the latest news stories about GRAPHITE BIO INC that investors may wish to consider to help them evaluate GRPH as an investment opportunity.
What Makes Graphite Bio, Inc. (GRPH) a New Buy StockGraphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
LENZ Therapeutics and Graphite Bio Announce Merger AgreementSAN DIEGO & SOUTH SAN FRANCISCO, Calif., November 15, 2023--LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. (NASDAQ: GRPH) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of |
We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn RateEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Graphite Bio Announces Departure of Chief Financial OfficerSOUTH SAN FRANCISCO, Calif., June 23, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensure an orderly transition. |
Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22%Key Insights Significant control over Graphite Bio by private equity firms implies that the general public has more... |
Should You Buy Graphite Bio (GRPH) Ahead of Earnings?Graphite Bio (GRPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
12 Gene Editing Stocks With the Best Long-Term PotentialIn this article, we will take a look at the 12 gene editing stocks with the best long-term potential. To see more such companies, go directly to 5 Gene Editing Stocks With the Best Long-Term Potential. Gene editing stocks are gaining ground on the back of an upbeat tone in the industry, helped by a […] |
11 Most Promising Gene Editing Stocks According to AnalystsIn this article, we will take a look at the 11 most promising gene editing stocks according to analysts. To see more such companies, go directly to 5 Most Promising Gene Editing Stocks According to Analysts. Genetics is one of the most promising areas where companies are pouring billions of dollars in R&D to find […] |
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial ResultsSOUTH SAN FRANCISCO, Calif., March 20, 2023--Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. |
Sickle-cell gene therapy developer stops program, cuts half of staffGene therapy offered hope for thousands of sickle cell disease patients. Now many are ending their programs. |